PTC Therapeutics Completes $550 Million Convertible Notes Offering

PTC Therapeutics Completes $550 Million Convertible Notes Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

PTC Therapeutics, Inc. (NASDAQ: PTCT), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders, announced the pricing and closing of a $550 million offering of 0% Convertible Senior Notes due 2031 pursuant to Rule 144A under the Securities Act of 1933, as amended.

WilmerHale advised PTC in the offering.

The WilmerHale team was led by Brian Johnson and Andrea Sorrentino and included Rachael Joseph, Sam Wizon, Brandon Hornlein, Nathan Moore and Meghan Walsh.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel